Harrow Re-Launches VERKAZIA for Pediatric Eye Disease, Targeting Unmet Need
HROW sits 18% above its 52-week low of $28.54.
Summary
Harrow re-launched VERKAZIA, a cyclosporine ophthalmic emulsion, for the treatment of vernal keratoconjunctivitis (VKC), a serious allergic eye disease primarily affecting children. This steroid-sparing therapy addresses a significant unmet need in pediatric eyecare. The re-launch is a strategic priority for Harrow, following recent Q1 2026 results that showed a wider net loss and negative operating cash flow. Successful commercialization of VERKAZIA could be a key factor in improving future revenue and profitability.
At the time of this announcement, HROW was trading at $33.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $28.54 to $54.85. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.